Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative clinical study of alilocumab (Praluent) and evorocumab (Repatha) for dyslipidemia

Next Previous
Trial Profile

Comparative clinical study of alilocumab (Praluent) and evorocumab (Repatha) for dyslipidemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2019

At a glance

  • Drugs Alirocumab (Primary) ; Evolocumab (Primary)
  • Indications Dyslipidaemias
  • Focus Therapeutic Use

    • Most Recent Events

    • 17 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 29 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top